Nanjing IASO Biotechnology Co., Ltd.
Recent events
Recent events tied to this brand in public sources.
Back to profile1 entries
2022
Sana, IASO Bio and Innovent announce BCMA CAR licensing agreement
Sana Biotechnology, IASO Bio and Innovent announced a strategic collaboration and non-exclusive license under which IASO Bio and Innovent granted Sana commercial rights to their clinically validated fully human BCMA CAR structure for specified in vivo gene therapy and ex vivo hypoimmune cell therapy product development. IASO Bio and Innovent are eligible for an upfront payment, development and regulatory milestones, and sales royalties.